Table 3. Average PFS, PD, and OS of the clinical data and the model.
| Items | Average PFS (m) | Mean difference | Average OS (m) | Mean difference |
Average PD (m) | Mean difference |
|||
|---|---|---|---|---|---|---|---|---|---|
| Dacomitinib | Gefitinib | Dacomitinib | Gefitinib | Dacomitinib | Gefitinib | ||||
| Clinical data* (48 months) | 18.33 | 13.12 | 5.21 | 30.29 | 29.32 | 0.97 | 11.96 | 16.20 | –4.24 |
| Model outcomes (120 months) | 24.81 | 13.89 | 10.92 | 41.52 | 44.47 | –2.95 | 16.71 | 30.58 | –13.87 |
*, a significant difference (P<0.05) was found in average PFS between dacomitinib and gefitinib in the clinical trial, but no statistical difference was found in average OS between dacomitinib and gefitinib in the clinical trial (P>0.05). PFS, progression-free survival; OS, overall survival; PD, progressive disease.